(I-BusinessNews.Com, November 11, 2019 ) Market Overview
• Orthobiologics, also called regenerative cellular therapies, are biological substances that can be used in helping injuries to heal more quickly. They are used to improve the healing of fractures, injured muscles, tendons, and ligaments. Orthobiologics are made from substances that naturally occur in the body, and when used in high concentration, they may assist in speed up the healing process. Orthobiologics find their use for the treatment of conditions such as spinal fusion, fracture recovery, and others. These are also available for the knee, hip, ankle, spine, wrist, and other body parts. The various products in Orthobiologics include bone grafts, platelet-rich plasma (PRP), autologous conditioned serum, stem cells, and growth factors.
Market Dynamics
• The global market for the orthobiologics Market is primarily driven by the rising geriatric population, prevalence of obesity, and increasing incidence of orthopedic disorders and musculoskeletal diseases. According to the United Nations (UN), an estimated 10% – 15% of all adults aged over 60 have some degree of Osteoarthritis, with the prevalence higher in women than men. According to the World Health Organization (WHO), 2016, more than 1.9 billion adults aged 18 years and older were overweight, of these over 650 million adults were obese. Moreover, the rise in several sports-related accidents and road accidents and the adoption of minimally invasive surgeries further propel the market. According to WHO, in 2018, approximately 37.3 million falls are severe enough to require medical attention occurred. The most substantial morbidity is arising in people aged 65 years or older. According to Anterior Cruciate Ligament (ACL) Injury Prevention, an article published in 2017, it was estimated that around 350,000 ACL reconstructions are performed annually in the USA and despite a surgical repair, approximately 79% of those individuals develop knee osteoarthritis, and 20% suffer re-injury within two years.
• However, the high cost of procedures, post-surgery complications, and stringent regulatory approval may hinder market progress.
Market Segmentation
• By Product, the global Orthobiologics market is segmented into Bone Morphogenetic Proteins (BMP), Demineralized Bone Matrix (DBM), Synthetic Bone Substitutes, Viscosupplements, Allografts, Stem cell, and others. Viscosupplements segment holds the most significant market share in Orthobiologics. It can be attributed to the high adoption rate of as it is widely available and favorable reimbursement policies. Viscosupplements advantage of being less-invasive, pain reduction, and having fewer side effects make it an attractive market. Moreover, the presence of strong product pipeline portfolios is expected to boost market development.
• By Application, the global Orthobiologics market is segmented into Osteoarthritis & Degenerative Arthritis, Spinal Fusion, Fracture Recovery, Soft Tissue Injuries, and Maxillofacial & Dental Applications. The Osteoarthritis & degenerative arthritis sector occupies the most significant Orthobiologics market share. It can be attributed to the presence of huge geriatric population, who are more prone to osteoarthritis. The United Nations estimated that by 2050 people aged over 60 will account for more than 20% of the world’s population, of which 15-20% (around 130 million people) are estimated to have symptomatic osteoarthritis. The spinal fusion segment is expected to be the fastest growing market share owing to the rising prevalence of spinal cord injuries, sports-related injuries, and accidents.
Geographical Analysis
• North America is the dominant share in the global Orthobiologics market, and it is primarily attributed to factors such as the increasing incidence of spinal disorders, rise in the geriatric population and obese population, and higher awareness about minimally invasive surgeries. Moreover, its broad base of the patient population and the established healthcare infrastructure and the rising disposable income and higher investment in R&D activities contribute to the growth of North America’s share. According to the National Spinal Cord Injury Database, 2018, the number of people with spinal cord injury (SCI) living in the United States is currently estimated to be approximately 288,000 persons. Moreover, about 20.7 million adults in the United States have degenerative joint disease. According to the American Academy of Orthopaedic Surgeons (AAOS), an estimated 4.7 million Americans have undergone total knee arthroplasty (TKA), and 2.5 million have undergone total hip arthroplasty (THA) and are living with implants. Additionally, favorable reimbursement policies for soft tissue healing and fusion enhancement products are expected to boost the regional market share.
• Asia-Pacific region is expected to be the fastest growing market during the forecast period, owing to the region’s rapidly improving healthcare infrastructure and the presence of a broad base of the target population. According to the International Osteoporosis Foundation (IOF), osteoporosis affects almost 70 million Chinese over the age of 50 and causes some 687,000 hip fractures in China each year.
Competitive Analysis
• Key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product drug, strong clinical pipeline and increasing R&D are other ways the leading players improve their market presence.
• In May 2019, Regenacell Therapy launched the Lipo-Pro System, a new and innovative adipose harvesting and processing device. This unique offering allows for the sourcing of adipose aspirate and subsequent adipose graft preparation at point of care by retaining the cellular component of both the graft and infranatant while removing of the acellular components of oil and remaining infranatant. It will provide a tool that allows physicians conducting autologous injection therapies.
• In May 2019, Anika Therapeutics, a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, announced plans to showcase its regenerative medicine and orthobiologics portfolio at the 12th Biennial International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS) Congress.
• In October 2018, Bone Therapeutics, a bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, announced the results of the first efficacy study of the Company’s enhanced viscosupplement, JTA-004, in patients with moderate symptomatic knee osteoarthritis, supporting future clinical development of the product. JTA-004 is a patented, non-cellular viscosupplement product for the treatment of knee osteoarthritis (KOA), which Bone Therapeutics has been developing in parallel with its core cell therapy pipeline and addressing its mission of bringing innovative solutions to orthopaedic conditions.
• In July 2018, Bioventus, a global leader in orthobiologic solutions, entered into a definitive agreement to divest its next generation bone morphogenetic protein (BMP) development program to a new company formed by Viscogliosi Brothers (VB), a private equity investment firm focused on developing innovative neuromusculoskeletal technologies. Bioventus acquired the exclusive, worldwide license to the BMP portfolio of development programs and associated intellectual property from Pfizer, in 2013. The portfolio, which will now be sold to VB, includes the next-generation BMP in development, as well as a BMP program for soft tissue indications.
Enquire Before Purchase: https://www.datamintelligence.com/enquiry/orthobiologics-market
Download free sample: https://www.datamintelligence.com/download-sample/orthobiologics-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
